|  |  |  |
| --- | --- | --- |
| **Supplementary Table 1: Patient Demographics and Treatment History** | | |
| **Sex** | **Number of Patients** | **%** |
| **Male** | **13** | **48%** |
| **Female** | **14** | **52%** |
| **Age** |  |  |
| **Median** | **60** |  |
| **Range** | **34-72** |  |
| **Diagnosis** |  |  |
| **Head and Neck cancer** | **4** | **15%** |
| **Sarcoma** | **4** | **15%** |
| **Renal Cell carcinoma** | **3** | **11%** |
| **Pancreatic cancer** | **3** | **11%** |
| **Colorectal cancer** | **2** | **7%** |
| **Metastatic Melanoma** | **2** | **7%** |
| **NSCLC** | **1** | **3.7%** |
| **Endometrial** | **1** | **3.7%** |
| **Adrenal** | **1** | **3.7%** |
| **Gastric** | **1** | **3.7%** |
| **Adenoid Cystic** | **1** | **3.7%** |
| **Cholangiocarcinoma** | **1** | **3.7%** |
| **Gastric neuro-ectodermal** | **1** | **3.7%** |
| **Prostate** | **1** | **3.7%** |
|  |  |  |
| **Performance Status (ECOG)** |  |  |
| **0** | **0** | **0%** |
| **1** | **27** | **100%** |
|  |  |  |
| **Prior Therapy** |  |  |
| **Median** | **4** |  |
| **Range** | **2-10** |  |
| **Surgery** | **20** |  |
| **Chemotherapy** | **18** |  |
| **Radiation Therapy** | **15** |  |
| **Molecular Therapy** | **12** |  |
| **Immunotherapy** | **5** |  |
| **Checkpoint Inhibitors** | **3** |  |

**Supplementary Table 1. Summary of patient demographics and treatment history**